On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials ...
Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...
The diagnostics advisory committee considered evidence on digital technologies for applying algorithms to spirometry from several sources. This included evidence submitted by 4 companies, a review of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results